1. Home
  2. BCAB vs LFVN Comparison

BCAB vs LFVN Comparison

Compare BCAB & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • LFVN
  • Stock Information
  • Founded
  • BCAB 2007
  • LFVN N/A
  • Country
  • BCAB United States
  • LFVN United States
  • Employees
  • BCAB N/A
  • LFVN N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • LFVN Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCAB Health Care
  • LFVN Health Care
  • Exchange
  • BCAB Nasdaq
  • LFVN Nasdaq
  • Market Cap
  • BCAB 96.2M
  • LFVN 127.0M
  • IPO Year
  • BCAB 2020
  • LFVN N/A
  • Fundamental
  • Price
  • BCAB $2.08
  • LFVN $12.18
  • Analyst Decision
  • BCAB Strong Buy
  • LFVN
  • Analyst Count
  • BCAB 2
  • LFVN 0
  • Target Price
  • BCAB $6.00
  • LFVN N/A
  • AVG Volume (30 Days)
  • BCAB 1.6M
  • LFVN 94.6K
  • Earning Date
  • BCAB 11-08-2024
  • LFVN 10-29-2024
  • Dividend Yield
  • BCAB N/A
  • LFVN 1.23%
  • EPS Growth
  • BCAB N/A
  • LFVN 15.00
  • EPS
  • BCAB N/A
  • LFVN 0.23
  • Revenue
  • BCAB N/A
  • LFVN $200,164,000.00
  • Revenue This Year
  • BCAB N/A
  • LFVN $4.36
  • Revenue Next Year
  • BCAB N/A
  • LFVN $3.85
  • P/E Ratio
  • BCAB N/A
  • LFVN $56.43
  • Revenue Growth
  • BCAB N/A
  • LFVN N/A
  • 52 Week Low
  • BCAB $1.14
  • LFVN $4.20
  • 52 Week High
  • BCAB $4.02
  • LFVN $14.71
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 55.80
  • LFVN 51.31
  • Support Level
  • BCAB $1.87
  • LFVN $11.68
  • Resistance Level
  • BCAB $2.13
  • LFVN $14.71
  • Average True Range (ATR)
  • BCAB 0.12
  • LFVN 0.79
  • MACD
  • BCAB 0.00
  • LFVN -0.05
  • Stochastic Oscillator
  • BCAB 68.90
  • LFVN 19.04

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About LFVN Lifevantage Corporation (Delaware)

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system, as well as Canine Health, a companion pet supplement formulated to combat oxidative stress in dogs. Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

Share on Social Networks: